The Efficacy of CASAD in Patients With Diarrhea Related to Medullary Thyroid Cancer
| Status: | Completed |
|---|---|
| Conditions: | Cancer, Irritable Bowel Syndrome (IBS), Endocrine, Gastrointestinal, Thyroid Cancer |
| Therapuetic Areas: | Endocrinology, Gastroenterology, Oncology |
| Healthy: | No |
| Age Range: | Any |
| Updated: | 4/2/2016 |
| Start Date: | November 2012 |
| End Date: | December 2013 |
| Contact: | Maria E Cabanillas, MD |
| Email: | mcabani@mdanderson.org |
Diarrhea in patients with MTC (Medullary Thyroid Cancer) can be debilitating and, in some
cases life threatening. Findings in such patients include volume depletion, renal
insufficiency, and electrolyte disorders. Diarrhea can also lead to increased cost of care,
reduced quality of life, and treatment delays. Not all patients benefit from conventional
anti-diarrheal therapy. CASAD is proven to reduce diarrhea in humans and animals. Clays have
water-binding effects, increase the absorptive capacity of the intestinal mucosa, and absorb
the excess cytokines which are possible mechanisms of diarrhea in MTC. In this study, we
will investigate if starting 1 g CASAD three times a day will ameliorate the severity of
diarrhea in patients with MTC. Diarrhea in patients with MTC can be debilitating and, in
some cases life threatening. Findings in such patients include volume depletion, renal
insufficiency, and electrolyte disorders. We hypothesize that adding CASAD 3 grams/day will
reduce the incidence and ameliorate the severity of diarrhea in patients with MTC.
cases life threatening. Findings in such patients include volume depletion, renal
insufficiency, and electrolyte disorders. Diarrhea can also lead to increased cost of care,
reduced quality of life, and treatment delays. Not all patients benefit from conventional
anti-diarrheal therapy. CASAD is proven to reduce diarrhea in humans and animals. Clays have
water-binding effects, increase the absorptive capacity of the intestinal mucosa, and absorb
the excess cytokines which are possible mechanisms of diarrhea in MTC. In this study, we
will investigate if starting 1 g CASAD three times a day will ameliorate the severity of
diarrhea in patients with MTC. Diarrhea in patients with MTC can be debilitating and, in
some cases life threatening. Findings in such patients include volume depletion, renal
insufficiency, and electrolyte disorders. We hypothesize that adding CASAD 3 grams/day will
reduce the incidence and ameliorate the severity of diarrhea in patients with MTC.
Inclusion Criteria:
- Patients with medullary thyroid cancer
- Men and women from all ethnic and racial groups
- Diarrhea ( >=3 loose bowel movements per day)
- Duration of diarrhea of at least 1 week
Exclusion Criteria:
- Patients with MEN 2b (since these patients may have megacolon)
- Patients taking any clay products
- History of significant neurological or psychiatric disorders that would impede giving
consent, treatment, or follow up.
- Patients who cannot comply with medications
- Patients whose current medication schedule would not permit an approximate 2 hour
window between administration of CASAD and other scheduled medications.
- Pregnancy or lactation
- Patients receiving systemic chemotherapy (includes tyrosine kinase inhibitors)
We found this trial at
1
site
Click here to add this to my saved trials
